Kendall A. Smith is an American scientist most well-known for his work on interleukins, the regulatory molecules of the immune system, which has led to many of the new present-day therapies for immunological disorders, transplant rejection, infectious diseases and cancer. [1] [2] Smith is a Professor Emeritus of Medicine at Weill Cornell Medicine. [3]
Kendall Arthur Smith was born in Akron, Ohio, where he grew up as the second child of Robert Lyman Smith and Juanita Murphy Smith. He attended Fairlawn Primary School, Simon Perkins Junior High School followed by Buchtel High School in Akron, graduating in 1960.
Smith graduated from Denison University, Granville, Ohio with a B.S. in biology (1964). [4] He graduated summa cum laude from the Ohio State University College of Medicine in 1968, then trained in Internal Medicine at Yale-New Haven Hospital (1968-1970). Smith then trained at the National Cancer Institute, Dartmouth Medical School and L’Institut de Cancerologie et d’Immunogenetique in Villejuif, France (1970-’74).
Smith joined the faculty of Dartmouth Medical School (Hanover, N.H.) as an Assistant Professor of Medicine in Hematology & Oncology in 1974, progressing to Associate Professor (1978) and Professor (1982). At the school, Smith focused his research on the immune system. By the 1970s, it had become clear that white blood cells are responsible for immune responses, but how these responses are initiated and regulated was not yet understood. The first molecularly defined T cell cytokine, interleukin-2 (IL-2), was originally described by Smith. [5] His findings had a significant impact on immunology research and paved the way for the discovery of numerous humoral mediators of cell-mediated immunity. [6] In groundbreaking research, Smith led a team that employed meticulous protein enrichment methods to purify TCGF (IL-2) to a state of purity and produce bioactive, biosynthetically radiolabeled TCGF. The introduction of radiolabeled TCGF/IL-2 allowed for an examination of its interaction with T cells, leading to a pivotal finding: the biological impacts of TCGF were facilitated by a high-affinity cytokine receptor that was selectively expressed on T cells activated through their T cell antigen receptor, thus underscoring the immune specificity of IL-2's effects. [6]
In 1993, Smith moved to Weill Cornell Medicine in New York City to conduct clinical research in AIDS. There he served as the Chief of The Division of Immunology as well as the Co-Chair of the Immunology Program of The Graduate School of Biomedical Sciences, a joint program between Cornell and Sloan-Kettering Institute. He also served as the Director of The Tr-Institutional MD/PhD Program, a joint effort between Cornell, Sloan-Kettering and the Rockefeller University. Having extended his research to the clinic, by 1999, Smith established that low, physiological doses of interleukins could stimulate immune responses without toxicity. [7] [8]
In 1993 Smith moved to Weill Cornell Medicine in New York City to conduct clinical research in AIDS. There he served as the Chief of The Division of Immunology as well as the Co-Chair of the Immunology Program of The Graduate School of Biomedical Sciences, a joint program between Cornell and Sloan-Kettering Institute. He also served as the Director of The Tr-Institutional MD/PhD Program, a joint effort between Cornell, Sloan-Kettering and the Rockefeller University.
This article needs additional or more specific
categories. (June 2021) |
Kendall A. Smith is an American scientist most well-known for his work on interleukins, the regulatory molecules of the immune system, which has led to many of the new present-day therapies for immunological disorders, transplant rejection, infectious diseases and cancer. [1] [2] Smith is a Professor Emeritus of Medicine at Weill Cornell Medicine. [3]
Kendall Arthur Smith was born in Akron, Ohio, where he grew up as the second child of Robert Lyman Smith and Juanita Murphy Smith. He attended Fairlawn Primary School, Simon Perkins Junior High School followed by Buchtel High School in Akron, graduating in 1960.
Smith graduated from Denison University, Granville, Ohio with a B.S. in biology (1964). [4] He graduated summa cum laude from the Ohio State University College of Medicine in 1968, then trained in Internal Medicine at Yale-New Haven Hospital (1968-1970). Smith then trained at the National Cancer Institute, Dartmouth Medical School and L’Institut de Cancerologie et d’Immunogenetique in Villejuif, France (1970-’74).
Smith joined the faculty of Dartmouth Medical School (Hanover, N.H.) as an Assistant Professor of Medicine in Hematology & Oncology in 1974, progressing to Associate Professor (1978) and Professor (1982). At the school, Smith focused his research on the immune system. By the 1970s, it had become clear that white blood cells are responsible for immune responses, but how these responses are initiated and regulated was not yet understood. The first molecularly defined T cell cytokine, interleukin-2 (IL-2), was originally described by Smith. [5] His findings had a significant impact on immunology research and paved the way for the discovery of numerous humoral mediators of cell-mediated immunity. [6] In groundbreaking research, Smith led a team that employed meticulous protein enrichment methods to purify TCGF (IL-2) to a state of purity and produce bioactive, biosynthetically radiolabeled TCGF. The introduction of radiolabeled TCGF/IL-2 allowed for an examination of its interaction with T cells, leading to a pivotal finding: the biological impacts of TCGF were facilitated by a high-affinity cytokine receptor that was selectively expressed on T cells activated through their T cell antigen receptor, thus underscoring the immune specificity of IL-2's effects. [6]
In 1993, Smith moved to Weill Cornell Medicine in New York City to conduct clinical research in AIDS. There he served as the Chief of The Division of Immunology as well as the Co-Chair of the Immunology Program of The Graduate School of Biomedical Sciences, a joint program between Cornell and Sloan-Kettering Institute. He also served as the Director of The Tr-Institutional MD/PhD Program, a joint effort between Cornell, Sloan-Kettering and the Rockefeller University. Having extended his research to the clinic, by 1999, Smith established that low, physiological doses of interleukins could stimulate immune responses without toxicity. [7] [8]
In 1993 Smith moved to Weill Cornell Medicine in New York City to conduct clinical research in AIDS. There he served as the Chief of The Division of Immunology as well as the Co-Chair of the Immunology Program of The Graduate School of Biomedical Sciences, a joint program between Cornell and Sloan-Kettering Institute. He also served as the Director of The Tr-Institutional MD/PhD Program, a joint effort between Cornell, Sloan-Kettering and the Rockefeller University.
This article needs additional or more specific
categories. (June 2021) |